City Therapeutics (NASDAQ:CTY – Get Free Report) was upgraded by analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.
City Therapeutics Stock Performance
CTY opened at $20.77 on Friday. City Therapeutics has a 52 week low of $19.75 and a 52 week high of $23.88.
Insider Activity at City Therapeutics
In other news, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the stock in a transaction that occurred on Monday, October 19th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the transaction, the insider directly owned 13,692,507 shares in the company, valued at approximately $246,465,126. This represents a 1.26% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Robert Nelsen acquired 170,000 shares of the company’s stock in a transaction on Monday, October 19th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the purchase, the director directly owned 13,692,507 shares in the company, valued at $246,465,126. This trade represents a 1.26% increase in their position. The disclosure for this purchase is available in the SEC filing.
City Therapeutics Company Profile
Further Reading
- Five stocks we like better than City Therapeutics
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
